All IndicationsCardiovascularPhase 3Phase 3Phase 2Phase 2Phase 2
❤️
Hypertension
4
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
NVS
Novartis AG
lisinopril
NVS
Novartis AG
Benazepril plus hydrochlorothiazide
ALNY
Alnylam Pharmaceuticals, Inc.
Zilebesiran
IONS
Ionis Pharmaceuticals, Inc.
Placebo
IONS
Ionis Pharmaceuticals, Inc.
ION904
AZN
AstraZeneca
Baxfendy
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVS Novartis AG | lisinopril | Phase 3 | — | — | — |
| NVS Novartis AG | Benazepril plus hydrochlorothiazide | Phase 3 | — | — | — |
| ALNY Alnylam Pharmaceuticals, Inc. | Zilebesiran | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | Placebo | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ION904 | Phase 2 | — | — | — |
| AZN AstraZeneca | Baxfendy | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
2
Phase 2
3
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.